{"id":"aripiprazole-desvenlafaxine-succinate-sustained-release","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1201728","moleculeType":"Small molecule","molecularWeight":"381.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole stabilizes dopamine neurotransmission by functioning as a partial agonist at D2 and D3 receptors, reducing excessive dopaminergic activity in psychosis while maintaining baseline tone. Desvenlafaxine, an active metabolite of venlafaxine, increases synaptic serotonin and norepinephrine by inhibiting their reuptake transporters, addressing mood and anxiety symptoms. This combination targets both the positive symptoms of psychosis and comorbid depression or anxiety.","oneSentence":"Aripiprazole acts as a dopamine D2/D3 receptor partial agonist while desvenlafaxine inhibits serotonin and norepinephrine reuptake, together addressing both psychotic and depressive symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:18:00.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant monotherapy"}]},"trialDetails":[{"nctId":"NCT01188668","phase":"PHASE4","title":"Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aripiprazole + desvenlafaxine succinate sustained release","genericName":"Aripiprazole + desvenlafaxine succinate sustained release","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole acts as a dopamine D2/D3 receptor partial agonist while desvenlafaxine inhibits serotonin and norepinephrine reuptake, together addressing both psychotic and depressive symptoms. Used for Adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant monotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}